Expanded Access for CC-10004

Official Title

Brief Summary

This is an expanded access program (EAP) for eligible participants designed to provideaccess to CC-10004.

Detailed Description

Not Provided

Status

No longer available

EA Type

Individual Patients

Conditions

Bechet's Disease

Interventions

Drug: CC-10004

CC-10004 will be administered orally
Other Name: Apremilast, Otezla

Eligibility Criteria

Inclusion Criteria:

- Exclusion Criteria:

-

Eligibility Gender

All

Eligibility Age

Minimum: N/A ~ Maximum: N/A

Countries

United States

Locations

Celgene
Summit, New Jersey, United States

Investigators

MD, Study Director
Amgen

NCT Number

NCT03740516

Keywords

Expanded Access

Compassionate Use

MeSH Terms

Apremilast

Disclaimer:

Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.

(202) 849 - 2075

1333 New Hampshire Ave, NW
Suite 420
Washington, DC 20036

navigator@reaganudall.org

Disclaimer:

Subscribe for updates from the Reagan-Udall Foundation for the FDA